NASDAQ:SIOX - Nasdaq - US8293991043 - Common Stock - Currency: USD
0.415
+0.01 (+2.09%)
The current stock price of SIOX is 0.415 USD. In the past month the price increased by 1.47%. In the past year, price decreased by -40.98%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2015-06-11. The firm is focused on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. The firm is primarily focused on pre-clinical research and development initiatives in gene therapy.
SIO GENE THERAPIES INC
1501 Broadway, 12Th Floor
New York City NEW YORK 10036 US
CEO: Pavan Cheruvu
Employees: 12
Company Website: https://siogtx.com/
Phone: 18777464891.0
The current stock price of SIOX is 0.415 USD. The price increased by 2.09% in the last trading session.
The exchange symbol of SIO GENE THERAPIES INC is SIOX and it is listed on the Nasdaq exchange.
SIOX stock is listed on the Nasdaq exchange.
7 analysts have analysed SIOX and the average price target is 5.1 USD. This implies a price increase of 1128.92% is expected in the next year compared to the current price of 0.415. Check the SIO GENE THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SIO GENE THERAPIES INC (SIOX) has a market capitalization of 30.70M USD. This makes SIOX a Nano Cap stock.
SIO GENE THERAPIES INC (SIOX) currently has 12 employees.
SIO GENE THERAPIES INC (SIOX) has a support level at 0.41 and a resistance level at 0.42. Check the full technical report for a detailed analysis of SIOX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SIOX does not pay a dividend.
SIO GENE THERAPIES INC (SIOX) will report earnings on 2023-06-12, before the market open.
SIO GENE THERAPIES INC (SIOX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.68).
ChartMill assigns a technical rating of 3 / 10 to SIOX. When comparing the yearly performance of all stocks, SIOX is a bad performer in the overall market: 81.9% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SIOX. While SIOX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SIOX reported a non-GAAP Earnings per Share(EPS) of -0.68. The EPS increased by 2.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to SIOX. The Buy consensus is the average rating of analysts ratings from 7 analysts.